Meters & Monitors
Blood Glucose Meters  Current Continuous Monitors Comparison of Available Monitors  Various Future Monitors Improving Today's Meters Other Monitors Older Monitors
Future Monitoring
AiMedics A.Menarini Diagnostics Cybiocare OHD InLight Solutions Integrated Applications Kumetrix LighTouch Medical Optiscan Orsense Oxygen Biotherapeutics Sensors For Medicine and Science Sensys Medical Sentek Solianis Sontra SpectRx Oxygen Biotherapeutics Visual Pathways
Oxygen Biotherapeutics - Implantable Glucose Biosensor 
Oxygen Biotherapeutics is a biomedical product development company specializing in creating innovative pharmaceuticals and medical devices in the fields of liquid ventilation, oxygen therapeutics, blood substitutes, and implanted glucose sensing. Many of their technology platforms are based on the pioneering research of Dr. Leland Clark, developer of the first heart-lung machine and the Clark oxygen and glucose biosensor electrodes.
Product development at SYBD is taking place on several innovative technological platforms, including the Glucose Biosensor. The implanted Glucose Biosensor continuously monitors blood glucose without the need for finger sticks. SYBD's implanted biosensor can be programmed to monitor blood glucose according to a predetermined schedule, thus eliminating problems of patient compliance. The sensor alarms for dangerous, life threatening conditions such as hypoglycemia.
The device is said to be made with similar materials you would find in a cardiac-pacemaker. New patents related to the sensor include an encased titanium battery and microprocessor as well a glucose oxidase enzyme system encapsulated in a semipermiable cellophane acetate membrane which provides continuous, accurate monitoring of blood glucose. Results are displayed as a digital readout in a wearable beeper-sized device that it hopes will have an implant life of over one year.
In September of 2008, they announced that they would be licensing its glucose biosensor technology to Glucometrics, Inc. for applications involving the measurement and monitoring of glucose levels in diabetes patients. Oxygen Biotherapeutics reported that they were unable to spend the necessary time developing the sensor.
"I am proud to announce this major milestone in our corporate history with our first-ever license agreement. Because of our focus and the priority we've placed on development of applications for Oxycyte(R), we were just not able to put the required amount of resources into the development of the biosensor. With this agreement, the biosensor intellectual property can be developed to its full potential with the possibility of generating a future royalty stream for our shareholders,"
Chris J. Stern, DBA, Company Chairman and CEO
About Glucometrics, Inc.
Glucometrics, Inc. is a start-up firm co-founded by Alan Brunsman and EnteraTech, Inc. Brunsman is a world-recognized expert in the field of glucose sensing and is a co-inventor of the current FDA gold standard glucose sensing technology as well as Oxygen Biotherapeutics' glucose biosensing technology. EnteraTech, Inc. is led by Bill Timmons, Ph.D., a seasoned technology entrepreneur and expert in funding technology startup firms. Glucometrics is poised to realize the founders' vision of a continuous, accurate, and affordable glucose sensing system. |
